1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates ...
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Patients who were randomized to neoadjuvant FOLFOX vs standard chemoradiation had similar disease-free and overall survival rates. 2. There ...
1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study ...
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37% to 70% ...
1. A randomized controlled trial of patients with stage II and III rectal cancer found that adding oxaliplatin to the ...
1. Although combining pembrolizumab to chemoradiotherapy as part of total neoadjuvant therapy after FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) treatment was ...
1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first ...
